A 6-month Randomised, Double-blind, Placebo Controlled Multicentre Parallel Group Study to Evaluate Efficacy and Safety of Bumetanide 0.5mg Twice a Day Followed by an Open Label Active 6-month Treatment Period With Bumetanide (0.5mg Twice a Day) and a 6 Weeks Discontinuation Period After Treatment Stop
Latest Information Update: 25 Sep 2023
At a glance
- Drugs Bumetanide (Primary)
- Indications Pervasive child development disorders
- Focus Registrational; Therapeutic Use
- Sponsors Servier
- 10 Apr 2022 This trial has been completed in Spain (End Date: 13 Sep 2021), according to European Clinical Trials Database record.
- 06 Apr 2022 This trial has been completed in Portugal and Slovakia (Date of the global end of the trial : 13-Sep-2021), according to European Clinical Trials Database record.
- 24 Oct 2021 This trial has been completed in Netherlands, according to European Clinical Trials Database record. (2021-09-13)